KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2026)

Amneal Pharmaceuticals has reported Gross Margin over the past 9 years, most recently at 36.5% for Q4 2025.

  • For Q4 2025, Gross Margin rose 51.0% year-over-year to 36.5%; the TTM value through Dec 2025 reached 36.88%, up 36.0%, while the annual FY2025 figure was 36.88%, 36.0% up from the prior year.
  • Gross Margin for Q4 2025 was 36.5% at Amneal Pharmaceuticals, up from 34.92% in the prior quarter.
  • Over five years, Gross Margin peaked at 39.71% in Q2 2021 and troughed at 30.77% in Q4 2023.
  • A 5-year average of 35.99% and a median of 36.05% in 2024 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: surged 4526bps in 2021 and later plummeted -456bps in 2023.
  • Year by year, Gross Margin stood at 30.99% in 2021, then increased by 14bps to 35.32% in 2022, then decreased by -13bps to 30.77% in 2023, then rose by 17bps to 35.98% in 2024, then increased by 1bps to 36.5% in 2025.
  • Business Quant data shows Gross Margin for AMRX at 36.5% in Q4 2025, 34.92% in Q3 2025, and 39.51% in Q2 2025.